COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02276066
Recruitment Status : Active, not recruiting
First Posted : October 27, 2014
Last Update Posted : May 18, 2020
Sponsor:
Collaborators:
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This study investigates the mechanism by which kidney dysfunction perpetuates inflammation, immunosuppression, and catabolism (PICS) in chronic critical illness. The investigators will test the hypothesis that persistent kidney dysfunction in sepsis associated by chronic critical illness contributes to decreased survival through the development of PICS. In chronic critical illness, the persistence of the inflammatory state may lead to capillary rarefication in the kidney causing accelerated chronic kidney disease. Progression of chronic kidney disease during chronic critical illness can drive PICS. Indeed, many of the features of chronic critical illness are consistent with the protein-energy malnutrition and muscle wasting associated with chronic kidney disease. Thus, the kidney can play a contributory role in chronic critical illness and PICS.

Condition or disease Intervention/treatment Phase
Sepsis Other: Iohexol Other: Urine Collection Other: Blood samples Not Applicable

Detailed Description:

The main goal of this project is to measure kidney filtration function at day 14 or the day of discharge from hospital (whichever occurs first), in order to determine the presence and magnitude of persistent kidney dysfunction after sepsis episode and to longitudinally assess further decline of kidney function at one year follow-up. The measure of the glomerular filtration rate (GRF) in patients with chronic critical illness and controls (sepsis patients discharged from ICU before day 14) will be used to determine to what degree of kidney dysfunction contributes to decreased survival and increase in chronic kidney disease at year one after sepsis onset.

One and/or all of the three ways for GFR assessment will be used, both at approximately day 14 or approximately at the day of discharge from the ICU and at the one year follow up :

  1. Determine clearance of Iohexol from blood after Iohexol injection and/or
  2. Determine apperance of Iohexol in urine after Iohexol injection (this would be the same injection as in one, and would not require two injections) and/or
  3. A timed urine collection to determine clearance of urea and creatinine and/or
  4. Estimated GFR using calculations with serum creatinine and cystatin C,

This will provide an opportunity to validate the different measurements.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle. Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Actual Study Start Date : February 2015
Actual Primary Completion Date : November 20, 2019
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis
Drug Information available for: Iohexol

Arm Intervention/treatment
Active Comparator: Inhospital group at day 14
This group of sepsis participants will remain hospitalized after day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
Other: Iohexol
Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
Other Name: omnipaque

Other: Urine Collection
Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.

Other: Blood samples
Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.

Released from hosptial prior to day 14
This group of sepsis participants will be released from the hospital prior to day 14. A normal saline dilution of Iohexol 0.5-1 ml will be given IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year. In addition to or as an option would be to have a timed urine collection to determine clearance of urea and creatinine can be performed instead of the saline dilution of Iohexol 0.5-1 ml and/or an estimated of GFR using serum creatinine and cystatin C measurement using calculations from blood samples.
Other: Iohexol
Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
Other Name: omnipaque

Other: Urine Collection
Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.

Other: Blood samples
Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.




Primary Outcome Measures :
  1. Area under the curve versus time curve (AUC) of Iohexol [ Time Frame: 0, 1, 2, 3, and 4 hours post-dose ]
    The decline in iohexol glomerular filtration rate at day 14 and 1 year follow-up between chronic crucial illness and control groups.


Secondary Outcome Measures :
  1. Serum Creatinine [ Time Frame: Day 14 ]
    The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.

  2. Serum Creatinine [ Time Frame: 1 year ]
    The correlation between iohexol glomerular filtration rate and estimated glomerular filtration rate using previously validated equation applied to serum creatinine in both groups.

  3. Urine Urea Concentration [ Time Frame: Day 14 ]
    The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.

  4. Urine Urea Concentration [ Time Frame: 1 year ]
    The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of urea concentration.

  5. Urine Creatinine Ratio [ Time Frame: Day 14 ]
    The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.

  6. Urine Creatinine Ratio [ Time Frame: 1 year ]
    The urine will be collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Presence in the surgery or trauma ICU
  • Age of ≥18 years
  • Entrance into our sepsis protocol
  • Ability to obtain informed consent.

Exclusion Criteria:

  • Expected lifespan of the patient is less than 3 months due to severe pre-existing comorbidities (ex. recurrent, advanced or metastatic cancer)
  • Severe traumatic brain injury (evidence of neurologic injury on CT scan and a GCS <8)
  • Refractory shock (i.e., patients who die within 12 hours)
  • Uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel)
  • Patient or patient's family are not committed to aggressive management of the patient's condition and/or the patient has a DNR/DNI on file.
  • Severe CHF (NY Heart Association Class IV)
  • Child-Pugh C liver disease or pre-liver transplant.
  • Known HIV infection with CD4 count <200 cells/mm3
  • Organ transplant recipient on immunosuppressive agents
  • Known pregnancy and mother's that are breastfeeding
  • Prisoners
  • Institutionalized patients
  • Inability to obtain informed consent.
  • Chemotherapy or radiotherapy within 30 days prior to sepsis.
  • End stage renal disease on admission.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02276066


Locations
Layout table for location information
United States, Florida
UF Health at Shands hospital
Gainesville, Florida, United States, 32610
Sponsors and Collaborators
University of Florida
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Investigators
Layout table for investigator information
Principal Investigator: Mark Segal, M.D. University of Florida
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02276066    
Other Study ID Numbers: IRB201400795-N
P50GM111152-01 ( U.S. NIH Grant/Contract )
First Posted: October 27, 2014    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Florida:
kidney dysfunction
chronic critical illness
sepsis
Glomerular filtration rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes